This website is for UK Healthcare Professionals only

*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022

Resources

Downloadable materials for healthcare professionals

Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

VENCLYXTO dosing and administration presentation


UK-VNCCLL-210189

Information on VENCLYXTO titration


UK-VNCCLL-210460
UK-VNCCLL-210459

Dosing and Administration Booklet


UK-VNCCLL-210462

TLS management tool


UK-VNCCLL-210461


Downloadable materials for your patients

Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

 

VENCLYXTO + obinutuzumab in 1L CLL


UK-VNCCLL-210267

VENCLYXTO + Rituximab in R/R CLL


UK-VNCCLL-210265

VENCLYXTO monotherapy in R/R CLL


UK-VNCCLL-210270

A guide to completing treatment with VENCLYXTO


UK-VNCCLL-210092

CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

References

  1. VENCLYXTO Summary of Product Characteristics.
  2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
  3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.

 

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-VNCCLL-220193. Date of preparation: May 2022